| scholarly article | Q13442814 |
| P2093 | author name string | G Baffet | |
| A Fautrel | |||
| A Bessard | |||
| F Ezan | |||
| C Frémin | |||
| L Gailhouste | |||
| P2860 | cites work | Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality | Q24794430 |
| Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis | Q24805089 | ||
| Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice | Q28137811 | ||
| The Ras-Raf-MEK-ERK pathway in the treatment of cancer | Q28207442 | ||
| Biochemical Characteristics of Caspases-3, -6, -7, and -8 | Q28250824 | ||
| Progress towards in vivo use of siRNAs | Q28297652 | ||
| Specificity and mechanism of action of some commonly used protein kinase inhibitors | Q28344791 | ||
| A synthetic inhibitor of the mitogen-activated protein kinase cascade | Q28367955 | ||
| Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo | Q28368373 | ||
| PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo | Q28609356 | ||
| Analysis of gene function in somatic mammalian cells using small interfering RNAs | Q29616541 | ||
| RNA interference: from gene silencing to gene-specific therapeutics | Q33215530 | ||
| The mitogen-activated protein kinase kinase/extracellular signal-regulated kinase cascade activation is a key signalling pathway involved in the regulation of G(1) phase progression in proliferating hepatocytes | Q33959204 | ||
| An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development | Q34250525 | ||
| Clinical experience of MEK inhibitors in cancer therapy | Q34595700 | ||
| Increased MAPK Expression and Activity in Primary Human Hepatocellular Carcinoma | Q34741778 | ||
| Mechanism in the sequential control of cell morphology and S phase entry by epidermal growth factor involves distinct MEK/ERK activations | Q34991305 | ||
| Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways | Q35054868 | ||
| The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. | Q35081944 | ||
| Targeting the mitogen-activated protein kinase cascade to treat cancer | Q35968411 | ||
| Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels | Q36421040 | ||
| Mechanisms of drug inhibition of signalling molecules | Q36488752 | ||
| Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation | Q36525558 | ||
| Protein kinases as drug targets in cancer. | Q36651764 | ||
| “Spontaneous” neoplastic transformation in vitro of epithelial cell strains of rat liver: Cytology, growth and enzymatic activities | Q39233042 | ||
| MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells | Q40147018 | ||
| Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor | Q40164535 | ||
| Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. | Q40192837 | ||
| No induction of anti-viral responses in human cell lines HeLa and MCF-7 when transfecting with siRNA or siLNA. | Q40316774 | ||
| The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib | Q40328353 | ||
| Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. | Q40414460 | ||
| A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics | Q40554467 | ||
| Distinct patterns of cyclin D1 regulation in models of liver regeneration and human liver | Q42485286 | ||
| GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells | Q42509048 | ||
| ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. | Q42799732 | ||
| Extracellular signal-regulated protein kinase 2 is required for efficient generation of B cells bearing antigen-specific immunoglobulin G. | Q42952003 | ||
| RNA interference in mammalian cells by chemically-modified RNA. | Q44496696 | ||
| The MAP kinase pathway is required for entry into mitosis and cell survival. | Q44737512 | ||
| In vitro and in vivo metabolism of the anti-cancer agent CI-1040, a MEK inhibitor, in rat, monkey, and human | Q45117950 | ||
| Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies | Q46595207 | ||
| The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel | Q46825496 | ||
| Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo | Q50693372 | ||
| The role of erk1 and erk2 in multiple stages of T cell development | Q50954940 | ||
| ERK2 but not ERK1 plays a key role in hepatocyte replication: an RNAi-mediated ERK2 knockdown approach in wild-type and ERK1 null hepatocytes | Q53562757 | ||
| Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. | Q54707687 | ||
| Growth factor dependence of progression through G1 and S phases of adult rat hepatocytes in vitro. Evidence of a mitogen restriction point in mid-late G1 | Q71070506 | ||
| Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma | Q74428408 | ||
| P433 | issue | 40 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5315-5325 | |
| P577 | publication date | 2008-06-02 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo | |
| P478 | volume | 27 |
| Q39215469 | Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration |
| Q39846471 | Atorvastatin Prevents Glutamate Uptake Reduction Induced by Quinolinic Acid Via MAPKs Signaling. |
| Q37399265 | BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells |
| Q33634659 | Cordyceps bassiana inhibits smooth muscle cell proliferation via the ERK1/2 MAPK signaling pathway |
| Q33517129 | Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways |
| Q52689774 | Dictyostelium Erk2 is an atypical MAPK required for chemotaxis |
| Q30541429 | Dissecting genealogy and cell cycle as sources of cell-to-cell variability in MAPK signaling using high-throughput lineage tracking |
| Q22001537 | EBP50 exerts tumor suppressor activity by promoting cell apoptosis and retarding extracellular signal-regulated kinase activity |
| Q35636272 | ERK pathway activation bidirectionally affects visual recognition memory and synaptic plasticity in the perirhinal cortex |
| Q39778248 | ERK-regulated differential expression of the Mitf 6a/b splicing isoforms in melanoma |
| Q51179467 | ERK1 Directly Interacts With JNK1 Leading to Regulation of JNK1/c-Jun Activity and Cell Transformation |
| Q26744787 | ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy? |
| Q45354269 | ERK1/2 promotes cigarette smoke-induced rat pulmonary artery smooth muscle cells proliferation and pulmonary vascular remodeling via up-regulating cycline1 expression |
| Q41382132 | ERK2 and JNK1 contribute to TNF-α-induced IL-8 expression in synovial fibroblasts. |
| Q34768262 | ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. |
| Q33520834 | Effects of estrogens and bladder inflammation on mitogen-activated protein kinases in lumbosacral dorsal root ganglia from adult female rats |
| Q37392045 | Experimental animal model and RNA interference: a promising association for bladder cancer research. |
| Q35894374 | Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma. |
| Q41521854 | Extracellular signal-regulated kinase 2 (ERK2) mediates phosphorylation and inactivation of nuclear interaction partner of anaplastic lymphoma kinase (NIPA) at G2/M. |
| Q24317342 | FAM83D activates the MEK/ERK signaling pathway and promotes cell proliferation in hepatocellular carcinoma |
| Q33836237 | Growth arrest signaling of the Raf/MEK/ERK pathway in cancer |
| Q35529018 | IRX1 influences peritoneal spreading and metastasis via inhibiting BDKRB2-dependent neovascularization on gastric cancer |
| Q33359985 | Immunolocalization of dually phosphorylated MAPKs in dividing root meristem cells of Vicia faba, Pisum sativum, Lupinus luteus and Lycopersicon esculentum. |
| Q38838612 | Increasing 3D Matrix Rigidity Strengthens Proliferation and Spheroid Development of Human Liver Cells in a Constant Growth Factor Environment. |
| Q42822951 | Lentiviral Vectors to Study the Differential Function of ERK1 and ERK2 MAP Kinases |
| Q33810552 | MAP kinases have different functions in Dictyostelium G protein-mediated signaling |
| Q39264596 | MAPK signaling in cisplatin-induced death: predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells |
| Q24621902 | MAPKs in development: insights from Dictyostelium signaling pathways |
| Q37802466 | Mitogen-activated protein kinases in hepatocellular carcinoma development |
| Q36976203 | MyD88 in DNA repair and cancer cell resistance to genotoxic drugs. |
| Q39436650 | Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets |
| Q39150740 | Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway |
| Q38465081 | Ras/ERK1 pathway regulation of p27KIP1-mediated G1-phase cell-cycle arrest in cordycepin-induced inhibition of the proliferation of vascular smooth muscle cells |
| Q26742080 | Redundancy in the World of MAP Kinases: All for One |
| Q58607971 | Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2 |
| Q43465192 | Signal transduction disturbance related to hepatocarcinogenesis in mouse by prolonged exposure to Nanjing drinking water |
| Q39004686 | Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling. |
| Q47104024 | Small interfering RNA against ERK1/2 attenuates cigarette smoke-induced pulmonary vascular remodeling |
| Q39660386 | Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway |
| Q41343608 | Synergistic suppression of t(8;21)-positive leukemia cell growth by combining oridonin and MAPK1/ERK2 inhibitors |
| Q28484496 | Targeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells |
| Q43127784 | The Dictyostelium MAPK ERK1 is phosphorylated in a secondary response to early developmental signaling |
| Q36362544 | The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control |
| Q28474123 | The N-terminal domain of ERK1 accounts for the functional differences with ERK2 |
| Q54381191 | The complexity of ERK1 and ERK2 MAPKs in multiple hepatocyte fate responses. |
| Q39704415 | The expression and activation of ERK/MAPK pathway in human esophageal cancer cell line EC9706. |
| Q82493836 | Zinc Upregulates the Expression of Osteoprotegerin in Mouse Osteoblasts MC3T3-E1 Through PKC/MAPK Pathways |
Search more.